Assessing the druggability of protein-protein interactions by a supervised machine-learning method

被引:30
|
作者
Sugaya, Nobuyoshi [1 ]
Ikeda, Kazuyoshi [1 ]
机构
[1] PharmaDesign Inc, Div Res & Dev, Drug Discovery Dept, Chuo Ku, Tokyo 1040032, Japan
来源
BMC BIOINFORMATICS | 2009年 / 10卷
关键词
INTERACTION INHIBITORS; INTERACTION NETWORKS; SMALL MOLECULES; DRUG DISCOVERY; TARGETS; DATABASE; PROGRESS; SKI; EXPLORATION; GENE;
D O I
10.1186/1471-2105-10-263
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Protein-protein interactions (PPIs) are challenging but attractive targets of small molecule drugs for therapeutic interventions of human diseases. In this era of rapid accumulation of PPI data, there is great need for a methodology that can efficiently select drug target PPIs by holistically assessing the druggability of PPIs. To address this need, we propose here a novel approach based on a supervised machine-learning method, support vector machine (SVM). Results: To assess the druggability of the PPIs, 69 attributes were selected to cover a wide range of structural, drug and chemical, and functional information on the PPIs. These attributes were used as feature vectors in the SVM-based method. Thirty PPIs known to be druggable were carefully selected from previous studies; these were used as positive instances. Our approach was applied to 1,295 human PPIs with tertiary structures of their protein complexes already solved. The best SVM model constructed discriminated the already-known target PPIs from others at an accuracy of 81% (sensitivity, 82%; specificity, 79%) in cross-validation. Among the attributes, the two with the greatest discriminative power in the best SVM model were the number of interacting proteins and the number of pathways. Conclusion: Using the model, we predicted several promising candidates for druggable PPIs, such as SMAD4/SKI. As more PPI data are accumulated in the near future, our method will have increased ability to accelerate the discovery of druggable PPIs.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Assessing the druggability of protein-protein interactions by a supervised machine-learning method
    Nobuyoshi Sugaya
    Kazuyoshi Ikeda
    [J]. BMC Bioinformatics, 10
  • [2] Assessing the druggability of protein-protein interactions
    Barril, X.
    [J]. DRUGS OF THE FUTURE, 2007, 32 : 12 - 13
  • [3] Machine-learning techniques for the prediction of protein-protein interactions
    Sarkar, Debasree
    Saha, Sudipto
    [J]. JOURNAL OF BIOSCIENCES, 2019, 44 (04)
  • [4] Protein-Protein Interactions: Structures and Druggability
    Ascher, David B.
    Jubb, Harry C.
    Pires, Douglas E. V.
    Ochi, Takashi
    Higueruelo, Alicia
    Blundell, Tom L.
    [J]. MULTIFACETED ROLES OF CRYSTALLOGRAPHY IN MODERN DRUG DISCOVERY, 2015, : 141 - 163
  • [5] Druggability of constitutive protein-protein interactions
    Whitty, Adrian
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [6] Dr. PIAS: an integrative system for assessing the druggability of protein-protein interactions
    Sugaya, Nobuyoshi
    Furuya, Toshio
    [J]. BMC BIOINFORMATICS, 2011, 12
  • [7] Dr. PIAS: an integrative system for assessing the druggability of protein-protein interactions
    Nobuyoshi Sugaya
    Toshio Furuya
    [J]. BMC Bioinformatics, 12
  • [8] Predicting protein-protein interactions by a supervised learning classifier
    Huang, Y
    Frishman, D
    Muchnik, I
    [J]. COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2004, 28 (04) : 291 - 301
  • [9] Machine-learning techniques for the prediction of protein–protein interactions
    Debasree Sarkar
    Sudipto Saha
    [J]. Journal of Biosciences, 2019, 44
  • [10] Evaluation of Machine Learning Algorithms on Protein-Protein Interactions
    Saha, Indrajit
    Klingstrom, Tomas
    Forsberg, Simon
    Wikander, Johan
    Zubek, Julian
    Kierczak, Marcin
    Plewczynski, Dariusz
    [J]. MAN-MACHINE INTERACTIONS 3, 2014, 242 : 211 - 218